Implementation of Piperacillin-Tazobactam Continuous Infusions for Critically Ill Patients: A Single-Centre Retrospective Chart Review.

The Canadian journal of hospital pharmacy Pub Date : 2025-08-13 eCollection Date: 2025-01-01 DOI:10.4212/cjhp.3710
Kylie Landry, Meghan MacKenzie, Sarah Burgess, Paul Bonnar, Yahya Shabi, Glenn Patriquin, Karolynn Holland, Volker Eichhorn
{"title":"Implementation of Piperacillin-Tazobactam Continuous Infusions for Critically Ill Patients: A Single-Centre Retrospective Chart Review.","authors":"Kylie Landry, Meghan MacKenzie, Sarah Burgess, Paul Bonnar, Yahya Shabi, Glenn Patriquin, Karolynn Holland, Volker Eichhorn","doi":"10.4212/cjhp.3710","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In critically ill patients, pharmacokinetic variability can lead to inadequate antimicrobial concentrations. Antimicrobial resistance to β-lactam antibiotics is increasing among the nonfermenting gram-negative bacilli (NFGNB). Current guidelines recommend optimizing β-lactam pharmacokinetics/pharmacodynamics with prolonged infusion of these antibiotics. In 2019, a protocol for continuous infusion of piperacillin-tazobactam (P/T) was implemented in 2 intensive care units (ICUs) as a quality improvement initiative.</p><p><strong>Objectives: </strong>The primary objective was to describe and evaluate implementation of the practice change to continuous infusion of P/T. The secondary objectives were to describe ICU mortality and length of stay (LOS), identify safety incidents related to the protocol, and determine the prevalence of NFGNB and associated minimum inhibitory concentrations of P/T.</p><p><strong>Methods: </strong>This single-centre retrospective study involved a convenience sample of 200 patients who received 2 or more doses of P/T during an ICU admission between October 2020 and October 2022. Data on drug administration, characteristics of the hospital stay, and patient outcomes were collected from patients' digital records and the Critical Care Database of the study institution. Eight criteria for successful implementation of the protocol were established, with implementation deemed successful if at least 6 of these criteria were met.</p><p><strong>Results: </strong>Implementation of the continuous-infusion protocol was successful for 156 (78.0%) of the 200 ICU patients, 41 (20.5%) of the patients died during the ICU admission, and the median LOS in the ICU was 4.9 (interquartile range 2.4-10.7) days. No safety incidents were identified. The prevalence of NFGNB was 3.1% for all ICU patients over the 2-year study period.</p><p><strong>Conclusions: </strong>Implementation of the continuous-infusion protocol was successful in most patients. Areas for improvement include editing the order set, providing interprofessional education, and enhancing interprofessional collaboration.</p>","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 3","pages":"e3710"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12316688/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Canadian journal of hospital pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4212/cjhp.3710","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: In critically ill patients, pharmacokinetic variability can lead to inadequate antimicrobial concentrations. Antimicrobial resistance to β-lactam antibiotics is increasing among the nonfermenting gram-negative bacilli (NFGNB). Current guidelines recommend optimizing β-lactam pharmacokinetics/pharmacodynamics with prolonged infusion of these antibiotics. In 2019, a protocol for continuous infusion of piperacillin-tazobactam (P/T) was implemented in 2 intensive care units (ICUs) as a quality improvement initiative.

Objectives: The primary objective was to describe and evaluate implementation of the practice change to continuous infusion of P/T. The secondary objectives were to describe ICU mortality and length of stay (LOS), identify safety incidents related to the protocol, and determine the prevalence of NFGNB and associated minimum inhibitory concentrations of P/T.

Methods: This single-centre retrospective study involved a convenience sample of 200 patients who received 2 or more doses of P/T during an ICU admission between October 2020 and October 2022. Data on drug administration, characteristics of the hospital stay, and patient outcomes were collected from patients' digital records and the Critical Care Database of the study institution. Eight criteria for successful implementation of the protocol were established, with implementation deemed successful if at least 6 of these criteria were met.

Results: Implementation of the continuous-infusion protocol was successful for 156 (78.0%) of the 200 ICU patients, 41 (20.5%) of the patients died during the ICU admission, and the median LOS in the ICU was 4.9 (interquartile range 2.4-10.7) days. No safety incidents were identified. The prevalence of NFGNB was 3.1% for all ICU patients over the 2-year study period.

Conclusions: Implementation of the continuous-infusion protocol was successful in most patients. Areas for improvement include editing the order set, providing interprofessional education, and enhancing interprofessional collaboration.

实施哌拉西林-他唑巴坦持续输液危重患者:单中心回顾性图表回顾。
背景:在危重患者中,药代动力学变异性可导致抗菌药物浓度不足。非发酵革兰氏阴性杆菌(NFGNB)对β-内酰胺类抗生素的耐药性正在增加。目前的指南建议通过长时间输注这些抗生素来优化β-内酰胺的药代动力学/药效学。2019年,作为一项质量改进举措,在2个重症监护病房(icu)实施了持续输注哌拉西林-他唑巴坦(P/T)的方案。目的:主要目的是描述和评估持续输注P/T的实践变化的实施情况。次要目标是描述ICU死亡率和住院时间(LOS),确定与方案相关的安全事件,并确定NFGNB的患病率和相关的P/T最低抑制浓度。方法:这项单中心回顾性研究纳入了200名患者,这些患者在2020年10月至2022年10月期间在ICU住院期间接受了2次或更多剂量的P/T治疗。从患者的数字记录和研究机构的重症监护数据库中收集药物给药、住院特征和患者结局的数据。制定了成功执行议定书的8项标准,如果至少满足其中6项标准,则视为成功执行。结果:200例ICU患者中,156例(78.0%)患者成功实施持续输注方案,41例(20.5%)患者在ICU入院期间死亡,ICU中位生存时间为4.9天(四分位数间距2.4-10.7)。没有发现安全事故。在2年的研究期间,所有ICU患者的NFGNB患病率为3.1%。结论:在大多数患者中,持续输注方案的实施是成功的。需要改进的领域包括编辑订单集、提供跨专业教育和加强跨专业协作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信